tirzepatide and cardiac structure in obesity-related hfpef: summit cmr substudy | jacc | aha 2024
Published 5 days ago • 196 plays • Length 14:00Download video MP4
Download video MP3
Similar videos
-
17:18
insights from step-hfpef trial | esc heart failure 2024
-
3:33
lbct dapagliflozin by nt-probnp in hfmref or hfpef | esc congress 2022
-
9:01
dea-hf patients: intra-patient comparison of three diuretic regimens | esc heart failure 2024
-
6:42
how to maximize your results using semaglutide or tirzepatide
-
45:06
the new weight loss drugs ozempic, mounjaro (semaglutide, tirzepatide) | dr. spencer nadolsky
-
5:31
sglt-2 inhibitors - dapagliflozin, empagliflozin, canagliflozin & ertugliflozin
-
32:21
nov 22 2024 this week in cardiology
-
5:29
mineralocorticoid antagonism in heart failure | esc 2024
-
11:51
t-teer for severe tr: 1-year outcomes from triluminate | jacc | tct 2024
-
2:28
lbct dapagliflozin and atrial fibrillation in hfpef in deliver | esc congress 2022
-
4:17
functional tr, cto and crt in hfpef
-
16:45
interpreting the data with tirzepatide
-
0:42
do all attr-cm patients present with hfpef?
-
17:52
top cardiology trials of 2022
-
26:10
long-term management of right ventricular outflow tract dysfunction in repaired tetralogy of fallot
-
3:17
europcr 22: eastbourne registry indicates satefy of sirolimus-coated balloon